Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) a…

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...
Transformer on MSNOpinion

The problem with DeepSeek

Transformer Weekly: Preemption’s out the NDAA, OpenAI’s ‘code red,’ and Anthropic’s IPO prep ...

Why Recursion Pharamaceuticals Topped the Market Today

Recursion Pharmaceuticals ( RXRX +1.91%) was in the headlines on Monday, and for the right reason. One of the biotech company ...

Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial

By Sriparna Roy Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the ...
ArchDaily

Effortless Design? Exploring Architecture Tools That Enhance the Creative Design Process

Improving the design process with Rayon V3, an all-in-one architectural tool integrating AI, data, and collaborative ...
C&EN

A trio of AI methods tackles enzyme design

RFdiffusion2, RFdiffusion3, and Riff-Diff each solve different structural problems in computational enzyme design ...
Frontiers

High-Dimensional Representations in Brain and Machine: Vector Symbolic Architectures for Neural Computation

Recent advances in neuroscience, cognitive science, and artificial intelligence are converging on the need for representations that are at once distributed, ...